Search Results
Your search for this matches 25381 pages
Showing 25201 - 25250ASCO 2013: Surveillance Sufficient Follow-up for Most Patients with Stage I Seminoma
Surveillance appears to be sufficient for men with stage I seminoma treated with orchiectomy, sparing patients from side effects of adjuvant radiation or chemotherapy. In a long-term study presented at the 2013 ASCO Annual Meeting (Abstract 4502), 99.5% of men followed by surveillance alone...
Some Stage II/III HER2-positive Tumors May Be Treated with Targeted Therapy without Chemotherapy
Results from a multicenter phase II study of patients with locally advanced HER2-positive breast cancer who receive targeted therapy with trastuzumab (Herceptin) and lapatinib (Tykerb) “support the hypothesis that selected patients with HER2-positive tumors may not need...
FDA Clears Multicenter Trial of Treatment for Chemotherapy-related Hair Loss
The FDA has approved initiation of a multicenter trial of the DigniCap System, a scalp-cooling device for chemotherapy-related hair loss. The trial is the second and final phase of study for the DigniCap System. A pilot study previously conducted by researchers at the University of California San...
Potential New Way to Suppress Tumor Growth Discovered
Researchers at the University of California, San Diego, School of Medicine, and University of Rochester Medical Center have identified a new mechanism that appears to suppress tumor growth, opening the possibility of developing a new class of anticancer drugs. The findings were published in this...
Clinical Sequencing Technology Identifies New Targets in Diverse Cancers
Novel abnormalities in the FGFR gene, called FGFR fusions, were identified in a spectrum of cancers, and preliminary results with cancer cells harboring FGFR fusions suggested that some patients with these cancers may benefit from treatment with FGFR inhibitor drugs, according to data published in...
DNA Sequencing Reveals Mucosal Melanoma's Genetic Fingerprint
Scientists have found a molecular "bullseye" for a rare form of melanoma, opening up opportunities for novel targeted treatment, according to new research published in the Journal of Pathology. Whole genome and whole exome sequencing carried out at Cancer Research UK’s Paterson Institute for ...
ASCO 2013: Novel Heat Shock Protein Inhibitor Effective in Combination with Docetaxel as Second-line Therapy for Advanced Lung Cancer
A large randomized phase II study, GALAXY-1, found that a novel heat shock protein (Hsp) 90 inhibitor, ganetespib, when combined with docetaxel in second-line therapy, leads to longer overall survival compared to standard second-line docetaxel alone in patients with advanced lung adenocarcinoma...
ASCO 2013: More than 20% of African American Women Carry Inherited Mutations in at Least One Breast Cancer Susceptibility Gene
A genomic profiling study of African American women with breast cancer found that about one in five carries an inherited abnormality in at least 1 of 18 genes associated with breast cancer susceptibility. Such mutations were more prevalent among women with aggressive triple-negative breast cancer,...
ASCO 2013: Less Lymphedema with Axillary Radiotherapy than Node Dissection, but Comparable Disease Control
A European phase III clinical trial found that lymphedema was twice as common among women with sentinel lymph node–positive early breast cancer who had axillary lymph node dissection compared to those who had axillary radiotherapy. Overall and disease-free survival 5 years after treatment...
ASCO 2013: Weekly Paclitaxel Is Less Toxic but as Effective for Women with Higher-risk Early-stage Breast Cancer
Low-dose weekly administration of paclitaxel resulted in equal progression-free survival but reduced overall toxicity compared to every-2-week dose-dense administration for women with higher-risk early-stage breast cancer who have undergone surgery, according to a phase III randomized trial....
PTEN Variant Demonstrates Tumor Suppressor and Regression Activity in Human and Animal Tissue
A novel gene variant found in human and animal tissue may be a promising treatment for cancer, including breast and brain cancer, according to scientists from the Icahn School of Medicine at Mount Sinai. The variant, called PTEN-Long, may contribute to a cell’s healthy function and also...
Cytomegalovirus Might Speed Brain Cancer Growth
A study led by researchers at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) and Dana-Farber Cancer Institute suggests that cytomegalovirus, a virus that infects most adults in the United...
ASCO 2013: Adapting to Ongoing Shortages of Common Cancer Drugs
A survey of 214 U.S. oncologists and hematologists found that more than 80% encountered cancer drug shortages between March and September of 2012, and many reported that shortages affected the quality of patient care they were able to provide. As physicians were forced to substitute more expensive...
ASCO 2013: Cervical Cancer Screening Using Visual Inspection with Vinegar Reduces Mortality by 31% in Large Study in India
Cervical cancer mortality was reduced by 31% over a period of 15 years among women screened with biennial visual inspection with acetic acid (VIA), or vinegar, delivered by primary health workers in a large randomized study conducted among 150,000 women in India. The researchers estimate this...
ASCO 2013: 10 Years of Tamoxifen Better Than 5 in Reducing Breast Cancer Recurrence and Death
Ten years of adjuvant treatment with tamoxifen reduces breast cancer recurrence and mortality among women treated for early-stage estrogen receptor (ER)–positive breast cancer, according to results of the British phase III aTTom study. These findings, presented at the 2013 ASCO Annual Meeting ...
ASCO 2013: Sorafenib Stalls Growth of Treatment-resistant Differentiated Thyroid Cancer
A randomized phase III study found that the targeted drug sorafenib (Nexavar) stalls disease progression by 5 months in patients with metastatic differentiated thyroid cancer that has progressed despite standard radioactive iodine therapy. If approved in this setting by the U.S. Food and Drug...
ASCO 2013: Adding Bevacizumab to Standard First-line Chemoradiation for Glioblastoma Does Not Improve Overall Survival
A randomized phase III study found no improvement in overall survival after the addition of bevacizumab (Avastin) to standard first-line chemoradiation for glioblastoma. Patients who received bevacizumab also experienced more side effects compared to those treated with chemoradiation alone. The...
ASCO 2013: Adding Bevacizumab to Chemotherapy Significantly Improves Response Rates and Survival in Women with Advanced Cervical Cancer
Adding bevacizumab (Avastin) to chemotherapy regimens with or without a platinum drug improved outcomes for women with metastatic or relapsed cervical cancer treated in a randomized phase III study. Presenting the results at the 2013 ASCO Annual Meeting (Abstract 3), lead author Krishnansu Sujata...
ASCO President Clifford Hudis, MD, on the 2013 ASCO Annual Meeting
This year’s ASCO Annual Meeting was really exciting in two specific ways. First, we saw the development of high-tech novel therapies and combinations that effectively manipulate the immune system and extend survival in historically difficult-to-treat diseases, like metastatic melanoma (eg,...
ASCO 2013: Cetuximab Offers Survival Advantage over Bevacizumab When Combined with FOLFIRI for First-line Treatment of Advanced Colorectal Cancer
First-line cetuximab (Erbitux) plus FOLFIRI chemotherapy (leucovorin, fluorouracil [5-FU], irinotecan) offered a roughly 4-month survival advantage over bevacizumab (Avastin) plus FOLFIRI for patients with KRAS wild-type metastatic colorectal cancer in the German phase III clinical trial FIRE-3. A ...
In the Clinic: Trametinib in Unresectable or Metastatic Melanoma with BRAF V600E or BRAF V600K Mutation
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. Indication On May 29, 2013, trametinib (Mekinist) was...
ASCO 2013: No Increased Risk of Oral HPV Infections Reported in Long-term Partners of Patients with HPV-positive Oropharyngeal Cancers
Spouses and long-term partners of patients diagnosed with human papillomavirus (HPV)-positive oropharyngeal cancer were no more likely to test positive for oral HPV infection than people in the general population and have a low risk of HPV-related oropharyngeal cancer, according to the Human Oral...
ASCO 2013: Selumetinib Significantly Improves Progression-free Survival for Patients with Advanced Melanoma of the Eye
Progression-free survival was significantly improved for patients with metastatic melanoma of the eye (uveal melanoma) treated with selumetinib, according to the final analysis of data from a phase II crossover study presented at the 2013 ASCO Annual Meeting (Abstract CRA9003). Progression-free...
ASCO 2013: Nivolumab Produces Durable Responses in Patients with Stage IV Melanoma
Long-term follow-up results from an expanded phase I study indicate that nivolumab produced long-lasting responses in patients with stage IV melanoma. Overall, 33 out of 107 patients (31%) treated with five different doses of nivolumab experienced tumor shrinkage of at least 30% and responses were...
ASCO 2013: Adding GM-CSF to Ipilimumab Significantly Improves Survival for Patients with Metastatic Melanoma
Adding granulocyte-macrophage colony-stimulating factor (GM-CSF, Leukine) to ipilimumab (Yervoy) at a 10 mg/kg dose significantly improved survival compared to the same dose of ipilimumab alone, according to results of a proof-of-principle phase II trial. One year after the start of therapy,...
ASCO 2013: Anti–PD-1 Antibody Produces Durable, Ongoing Response in Patients with Advanced Melanoma
Preliminary results of an ongoing trial suggest that the anti–PD-1 antibody lambrolizumab has significant antitumor activity in patients with advanced melanoma and is well tolerated. The data were presented by Antoni Ribas, MD, PhD, Professor of Hematology/Oncology and Surgery, and Director...
ASCO 2013: Pazopanib Maintenance Therapy Delays Relapse of Advanced Ovarian Cancer
A phase III clinical trial has found that pazopanib (Votrient), an oral multikinase inhibitor, extends disease-free survival by an average of 5.6 months, compared to placebo, in women with advanced ovarian cancer who had initial successful treatment with surgery and chemotherapy. “Our...
Experts Call for Breast Cancer Trials Aimed at Younger Patients
A lack of clinical trials aimed specifically at younger patients with breast cancer could be partly to blame for their poor survival rates, according to a study published in the Journal of the National Cancer Institute. Study Details The study analyzed 2,956 women diagnosed with breast cancer...
New Method to Test Breast Lesions Could Better Detect Cancer and Reduce Repeat Biopsies
A newly developed, single-step Raman spectroscopy algorithm has the potential to simultaneously detect microcalcifications and enable diagnosis of the associated breast lesions with high precision, according to data published in Cancer Research, a journal of the American Association for Cancer...
ASCO 2013: For Patients with Metastatic Pancreatic Cancer, Both Treatment and Survival Decrease with Advanced Age
A new study by researchers Fox Chase Cancer Center has identified a disconnect between clinical trials that look at new treatments for metastatic pancreatic cancer and the patient population most likely to be diagnosed with the disease. Clinical trials typically enroll, and base their findings on,...
New Possibilities for Prostate Cancer Treatment
An Australian study has identified a subgroup of prostate cancer cells that survive androgen deprivation therapy and could contribute to prostate cancer recurrence. Previously unidentified, these cells are potential targets for future treatments. As they are present early in disease development,...
Researchers Identify Novel Class of Drugs for Prostate Cancers
A new study on prostate cancer describes a novel class of drugs developed by UT Southwestern Medical Center researchers that interrupts critical signaling needed for prostate cancer cells to grow. In men with advanced prostate cancer, growth of cancer cells depends on androgen receptor signaling,...
New Research Shows Significant Improvement in Overall Survival Outcomes for Patients Receiving Blood Stem Cell Transplants
Survival rates have increased significantly among patients who received blood stem cell transplants from both related and unrelated donors, according to a study published in the Journal of Clinical Oncology. The study authors attribute the increase to several factors, including advances in HLA...
Breaking News on Lymphoma and Myeloma to Be Reported at European Hematology Congress in Stockholm
In order to support high-quality science, the European Hematology Association collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research. In simultaneous sessions on Thursday, June 13, during the European...
EGFR Prevents Maturation of Cancer-fighting microRNAs under Hypoxia
Under conditions of oxygen starvation often encountered by tumors, the epidermal growth factor receptor (EGFR) sends signals that thwart the development of tumor-suppressing microRNAs, an international team led by scientists at The University of Texas MD Anderson Cancer Center discovered. The...
Mayo Clinic Genomic Analysis Lends Insight to Prostate Cancer
Mayo Clinic researchers have used next-generation genomic analysis to determine that some of the more aggressive prostate cancer tumors have similar genetic origins, which may help in predicting cancer progression. The findings appear online today in the journal Cancer Research. Gleason Patterns...
Intensified Liposomal Daunorubicin May Offer High Survival Rates without Added Cardiotoxicity for Children with Leukemia
Treating pediatric leukemia patients with a liposomal formulation of anthracycline-based chemotherapy at an intensified dose during initial treatment may result in high survival rates without causing any added heart toxicity, according to the results of a study published online in Blood, the...
Phase II Trial Targeting Genetic Anomaly in Castration-resistant Metastatic Prostate Cancer Underway
A new clinical trial is testing whether targeting treatments to a genetic anomaly can lead to better treatments for castration-resistant metastatic prostate cancer. The trial, led by investigators at the University of Michigan Comprehensive Cancer Center, is being conducted at 11 sites throughout...
Inflammatory Bowel Disease Raises Risk of Melanoma
Patients with inflammatory bowel disease are at higher risk of melanoma, reported researchers at Mayo Clinic. Researchers found that inflammatory bowel disease is associated with a 37% greater risk for the disease. The findings were presented at the Digestive Disease Week 2013 conference in...
Beta-blockers May Boost Chemotherapy Response in Neuroblastoma
Beta-blockers, normally used for high blood pressure, could enhance the effectiveness of chemotherapies in treating neuroblastoma, according to a new study published today in the British Journal of Cancer. Early Results Promising Researchers from the Children’s Cancer Institute Australia...
Genetic Diversity Predicts Outcomes in Head and Neck Cancer
A new measure of the heterogeneity of cells within a tumor appears to predict treatment outcomes of patients with the most common type of head and neck cancer. In the May 20 issue of the journal Cancer, investigators at Massachusetts General Hospital (MGH) and Massachusetts Eye and Ear...
Study: Gold Nanoparticles Can Help Fight Ovarian Cancer
Positively charged gold nanoparticles are usually toxic to cells, but cancer cells somehow manage to avoid nanoparticle toxicity. Mayo Clinic researchers found out why and determined how to make the nanoparticles effective against ovarian cancer cells. The discovery is detailed in the current...
Molecular Marker from Pancreatic 'Juices' Helps Identify Pancreatic Cancer
Researchers at Mayo Clinic have developed a promising method to distinguish between pancreatic cancer and chronic pancreatitis, two disorders that are difficult to tell apart. A molecular marker obtained from pancreatic “juices” can identify almost all cases of pancreatic cancer, their...
ASCO 2013: Routine Surveillance Imaging Scans Add Little to Detection of Relapse in Patients with Diffuse Large B-cell Lymphoma
A large study reports that the vast majority of diffuse large B-cell lymphoma relapses are detected based on symptoms, abnormal blood tests or abnormal findings on physical exam, suggesting that CT scans, which are currently a routine part of follow-up, may be unnecessary. Researchers found that...
ASCO 2013: Surveillance Following Surgery Is Sufficient for Men with Stage I Seminoma
A long-term study of men with stage I seminoma, a common form of testicular cancer, suggests that surveillance for cancer recurrence, rather than additional chemotherapy or radiation therapy, is sufficient for the vast majority of men who have undergone successful surgery for their cancer....
ASCO 2013: New Drug Targeting PI3K-delta Shows Strong Activity in Early Trial for High-risk Chronic Lymphocytic Leukemia
Results from a phase I study of a new oral targeted drug, idelalisib (GS-1101), show the agent has potential as a therapy for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL). The drug produced rapid and long-lasting tumor shrinkage in half of the patients treated with...
ASCO 2013: PARP Inhibitor Shows Activity in Pancreatic, Prostate Cancers among Patients Carrying BRCA Mutations
In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers ...
ASCO 2013: Standard-dose Radiation Is Superior to High-dose Radiation for Patients with Locally Advanced Stage III NSCLC Undergoing Chemotherapy
A phase III trial in patients with stage III non–small cell lung cancer (NSCLC) concluded that standard-dose radiotherapy (60 Gy) is safer and more effective than high-dose radiotherapy (74 Gy), extending survival by 9 months and causing fewer treatment-related deaths. While 60 Gy is already...
ASCO 2013: Anti–PD-L1 Drug Shows Promising Anticancer Effects in a Variety of Advanced Cancers
A phase I expansion study of the investigational drug MPDL3280A— an engineered PD-L1 targeted antibody—shows impressive tumor shrinkage rates in patients with several different cancers—including lung, melanoma, kidney, colorectal, and gastric cancers—that had progressed...
ASCO 2013: Men’s Fitness in Middle Age Protects against Developing and Dying from Cancer Later in Life
Findings from a large, prospective 20-year study indicate that a high level of cardiovascular fitness in middle age reduces men’s risk of developing and dying from lung and colorectal cancer, two of the most common cancers affecting men. Better fitness also reduces the risk of dying from,...
